Literature DB >> 19915843

Multimodality imaging in Europe: a survey by the European Association of Nuclear Medicine (EANM) and the European Society of Radiology (ESR).

Alberto Cuocolo1, Eamann Breatnach.   

Abstract

PURPOSE: Multimodality imaging represents an area of rapid growth with important professional implication for both nuclear medicine physicians and radiologists throughout Europe. As a preliminary step for future action aimed at improving the quality and accessibility of PET/SPECT/CT multimodality imaging practice in Europe, the European Association of Nuclear Medicine (EANM) and the European Society of Radiology (ESR) performed a survey among the individual membership of both societies to obtain information on the status of multimodality imaging in their facilities and their future visions on training for combined modalities.
METHODS: A questionnaire was forwarded to all individual members of the EANM and ESR. The main subject matter of the questionnaire related to: (1) study performance,current procedures, current equipment including its supervisory personnel at respondents' individual facilities and (2)vision of future practice, performance and the potential for combined interdisciplinary viewing and training for future professionals.
RESULTS: The reporting and the billing procedures of multimodality imaging studies are very heterogeneous in European countries. The majority of the members of both societies believe that the proportion of PET/CT conducted as a full diagnostic CT with contrast enhancement will increase over time. As expected, (18)F-FDG is the most commonly used PET tracer for clinical applications. The large majority of respondents were in favour of an interdisciplinary training programme being developed on a European level together by the EANM and the ESR and the respective sections of the European Union of Medical Specialists.
CONCLUSION: The results of this survey show that there is wide heterogeneity in the current practice of multimodality imaging in Europe. This situation may limit the full potential and integration of multimodality imaging within the clinical arena. There is a strong desire within both specialties for the development of interdisciplinary training to address some of these issues.

Mesh:

Year:  2010        PMID: 19915843     DOI: 10.1007/s00259-009-1250-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  2 in total

1.  White paper of the European Society of Radiology (ESR) and the European Association of Nuclear Medicine (EANM) on multimodality imaging.

Authors:  Nicholas Gourtsoyiannis; Iain McCall; Maximilian Reiser; Bruno Silberman; Angelika Bischof Delaloye; Ignacio Carrió; Alberto Cuocolo; Wolfram Knapp
Journal:  Eur Radiol       Date:  2007-08       Impact factor: 5.315

2.  White paper of the European Association of Nuclear Medicine (EANM) and the European Society of Radiology (ESR) on multimodality imaging.

Authors:  Angelika Bischof Delaloye; Ignasi Carrió; Alberto Cuocolo; Wolfram Knapp; Nicholas Gourtsoyiannis; Iain McCall; Maximilian Reiser; Bruno Silberman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08       Impact factor: 9.236

  2 in total
  9 in total

1.  Training for multimodality imaging.

Authors:  Patrick Bourguet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-04       Impact factor: 9.236

2.  The Young EANM Committee survey.

Authors:  Ozgul Ekmekcioglu; Imene Zerizer; Patrick Pilkington; André H Dias; Nevena Ristevska; François Jamar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03       Impact factor: 9.236

3.  Comparison of lesion detection and quantitation of tracer uptake between PET from a simultaneously acquiring whole-body PET/MR hybrid scanner and PET from PET/CT.

Authors:  Marco Wiesmüller; Harald H Quick; Bharath Navalpakkam; Michael M Lell; Michael Uder; Philipp Ritt; Daniela Schmidt; Michael Beck; Torsten Kuwert; Carl C von Gall
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-06       Impact factor: 9.236

4.  Hybrid cardiac imaging: SPECT/CT and PET/CT. A joint position statement by the European Association of Nuclear Medicine (EANM), the European Society of Cardiac Radiology (ESCR) and the European Council of Nuclear Cardiology (ECNC).

Authors:  Albert Flotats; Juhani Knuuti; Matthias Gutberlet; Claudio Marcassa; Frank M Bengel; Philippe A Kaufmann; Michael R Rees; Birger Hesse
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01       Impact factor: 9.236

5.  PET/CT without capacity limitations: a Danish experience from a European perspective.

Authors:  Poul Flemming Høilund-Carlsen; Oke Gerke; Mie Holm Vilstrup; Anne Lerberg Nielsen; Anders Thomassen; Søren Hess; Mette Høilund-Carlsen; Werner Vach; Henrik Petersen
Journal:  Eur Radiol       Date:  2011-01-28       Impact factor: 5.315

Review 6.  Role of Hybrid Brain Imaging in Neuropsychiatric Disorders.

Authors:  Amer M Burhan; Nicole M Marlatt; Lena Palaniyappan; Udunna C Anazodo; Frank S Prato
Journal:  Diagnostics (Basel)       Date:  2015-12-04

7.  PET/CT is a cost-effective tool against cancer: synergy supersedes singularity.

Authors:  Barbara Malene Fischer; Barry A Siegel; Wolfgang A Weber; Konrade von Bremen; Thomas Beyer; Antonis Kalemis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-05-13       Impact factor: 9.236

8.  Quantification of internal dosimetry in PET patients: individualized Monte Carlo vs generic phantom-based calculations.

Authors:  Sara Neira; Jacobo Guiu-Souto; Pablo Díaz-Botana; Paulino Pais; Carlos Fernández; Virginia Pubul; Álvaro Ruibal; Cristian Candela-Juan; Araceli Gago-Arias; Miguel Pombar; Juan Pardo-Montero
Journal:  Med Phys       Date:  2020-07-14       Impact factor: 4.071

9.  The Frequency of Focal Thyroid Incidental Findings and Risk of Malignancy Detected by 18F-Fluorodeoxyglucose Positron Emission Tomography in an Iodine Deficient Population.

Authors:  Nina Gedberg; Jesper Karmisholt; Michael Gade; Rune V Fisker; Victor Iyer; Lars J Petersen
Journal:  Diagnostics (Basel)       Date:  2018-07-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.